1.9M
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Gaurav Aggarwal | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Feb 2025 | 686 | 3,119 | - | - | Series A-2 Prime Preferred Stock | |
| Gaurav Aggarwal | Director | 18 Feb 2025 | 1,400,000 | 11,370,152 | - | - | Common Stock | ||
| Gaurav Aggarwal | Director | 09 Oct 2024 | 5,500,000 | 9,970,152 | - | - | Common Stock | ||
| Gaurav Aggarwal | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Oct 2024 | 2,695 | 3,885 | - | - | Series A-2 Prime Preferred Stock | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 81,750 | 2,119,862 | - | - | Stock Options | |
| John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 40,256 | 915,565 | - | - | Stock Options | |
| Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 81,750 | 2,055,000 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 232,868 | 6,439,505 | - | - | Stock Options | |
| John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 228,119 | 875,309 | - | - | Stock Options | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 463,250 | 2,038,112 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 1,319,583 | 6,206,637 | - | - | Stock Options | |
| Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 463,250 | 1,973,250 | - | - | Stock Options | |
| Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 1,355,000 | 1,510,000 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 4,684,775 | 4,988,798 | - | - | Stock Options | |
| John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 570,329 | 647,190 | - | - | Stock Options | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 1,355,000 | 1,574,862 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 79,252 | 79,252 | - | - | Warrant (right to buy | |
| Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 115,275 | 115,275 | - | - | Warrant (right to buy) | |
| Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 72,047 | 72,047 | - | - | Warrant (right to buy) | |
| Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 79,252 | 79,252 | - | - | Warrant (right to buy | |
| Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 50 | 0 | - | - | Series A-1 Convertible Preferred Stock | |
| Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 104,612 | 175,012 | - | - | Common Stock | |
| Shalabh K. Gupta | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 115,275 | 115,275 | - | - | Warrant (right to buy) | |
| Shalabh K. Gupta | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 104,612 | 2,527,449 | - | - | Common Stock | |
| Shalabh K. Gupta | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 50 | 0 | - | - | Series A-1 Convertible Preferred Stock | |
| Shalabh K. Gupta | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 72,047 | 72,047 | - | - | Warrant (right to buy) | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 41,845 | 41,845 | - | - | Common Stock | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 46,110 | 46,110 | - | - | Warrant (right to buy) | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 20 | 0 | - | - | Series A-1 Convertible Preferred Stock | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 31,700 | 31,700 | - | - | Warrant (right to buy | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 28,818 | 28,818 | - | - | Warrant (right to buy) | |
| Gaurav Aggarwal | Director | 11 Jul 2023 | 3,470,152 | 3,470,152 | - | - | Common Stock | ||
| Gaurav Aggarwal | Director | 11 Jul 2023 | 13,429,000 | 13,429,000 | - | - | Series A-2 Preferred Stock | ||
| Gaurav Aggarwal | Director | 11 Jul 2023 | 8,077 | 0 | - | - | Series A-1 Preferred Stock | ||
| Gaurav Aggarwal | Director | 11 Jul 2023 | 18,621,655 | 18,621,655 | - | - | Tranche C Warrants (right to buy) | ||
| Gaurav Aggarwal | Director | 11 Jul 2023 | 11,638,534 | 11,638,534 | - | - | Tranche B Warrants (right to buy) | ||
| Gaurav Aggarwal | Director | 11 Jul 2023 | 12,802,388 | 12,802,388 | - | - | Tranche A Warrants (right to buy) | ||
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 20 | 20 | - | - | Series A Convertible Preferred Stock | |
| Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 50 | 50 | - | - | Series A Convertible Preferred Stock | |
| Shalabh K. Gupta | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 50 | 50 | - | - | Series A Convertible Preferred Stock | |
| Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 8,077 | 8,077 | - | - | Series A-1 Convertible Preferred Stock | |
| Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 55,000 | 155,000 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 86,000 | 202,279 | - | - | Stock Options | |
| John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 35,000 | 76,861 | - | - | Stock Options | |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 28,000 | 219,862 | - | - | Stock Options | |
| Brigitte Schiller | Director | Purchase of securities on an exchange or from another person at price $ 0.82 per share. | 16 May 2022 | 15,000 | 15,000 | - | 0.8 | 12,375 | Common Stock |
| Pramod Gupta | EVP, Pharmaceuticals and BD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 34,884 | 191,862 | - | - | Stock Options | |
| Shalabh K. Gupta | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 116,279 | 218,023 | - | - | Stock Options | |
| John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 18,605 | 41,861 | - | - | Stock Options |